BRCA mutation-related Hereditary Breast and Ovarian Cancer
BRCA1 and BRCA2 genes are tumor suppressor gene that plays a role in DNA repair and cell proliferation control. An individual who has the BRCA mutation has risk up to 87 for developing breast cancer and 39-63% for developing ovarian cancer by age 70. The mutation in BRCA gene can be inherited to other generation. In addition, hereditary breast and ovarian cancer relates to BRCA1 and BRCA2 gene mutation which can be found about 10% in ovarian cancer and 3-5% of breast cancer.
Who should be tested BRCA mutation?
1. Individuals who have experienced with breast and/or ovarian cancer in family. The comprehensive testing which is BRCA mutation testing for point mutation and deletion/duplication, should be performed in an individual in the family who has had breast or ovarian cancer to identify a germline mutation pattern. If BRCA mutation presents and has been identified, other members should also be tested for the specific mutation.
2. A mutation in BRCA1 and BRCA2 occurs more frequently in some ancestry, including Ashkenazi Jewish
3. Advanced ovarian cancer individuals who need PARP inhibitor including Olaparib and Rucabarib, have to be tested for BRCA mutation to ensure that they are able to use these drugs.
N Health provides BRCA mutation testing which relates to hereditary breast and ovarian cancer as listed in the table below.
*This operation schedule is for the test performed at N Health head quarter, Bangkok .
**Above turnaround time does not include logistic time. For BDMS network hospitals, please contact N Health laboratory located at your hospitals.
4. ACOG Practice Bulletin No. 103: Hereditary Breast and Ovarian Cancer Syndrome. Obstetrics & Gynecology. 113(4):957-966, APR 2009.
Download N Test Breast Cancer
Download Infographic Breast Cancer